Alnylam Pharmaceuticals (ALNY) Other Non-Current Liabilities (2009 - 2026)

Alnylam Pharmaceuticals (ALNY) has 17 years of Other Non-Current Liabilities data on file, last reported at $7.6 million in Q1 2026.

• For the quarter ending Q1 2026, Other Non-Current Liabilities fell 98.2% year-over-year to $7.6 million; the trailing twelve-month figure through Mar 2026 stood at $7.6 million (down 98.2% YoY), and the FY2025 full-year result was $7.6 million, down 98.07% from the prior year.
• Other Non-Current Liabilities for Q1 2026 stood at $7.6 million, roughly flat from $7.6 million in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $439.7 million in Q3 2025 and bottomed at $7.6 million in Q4 2025.
• The 5-year median for Other Non-Current Liabilities is $280.7 million (2023), against an average of $261.8 million.
• The widest annual swing landed in 2022, when Other Non-Current Liabilities surged 139.37%; it then plunged 98.2% in 2026.
• A 5-year view of Other Non-Current Liabilities shows it stood at $212.6 million in 2022, then jumped by 45.09% to $308.4 million in 2023, then climbed by 27.46% to $393.1 million in 2024, then sank by 98.07% to $7.6 million in 2025, then grew by 0.22% to $7.6 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $7.6 million (Q1 2026), $7.6 million (Q4 2025), and $439.7 million (Q3 2025), per Business Quant data.

Peer Comparison